Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates
Executive Summary
While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.
You may also be interested in...
Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
Australia Becomes First Country To Regulate Psilocybin & MDMA As Medicines
The Therapeutic Goods Administration said its decision to down-schedule two psychedelic substances to controlled drug status followed extensive public consultation, a report from an independent expert panel, and advice from the Advisory Committee on Medicines Scheduling.
More De-Risking Required Before Pharma Dives Into Psychedelics
One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.